{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:33:28Z","timestamp":1789173208429,"version":"build-2803163510"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>We report head-to-head comparison of the bivalent and quadrivalent HPV vaccine efficacies against immediate precursors of cervical cancer from 15 years\u2019 country-wide cancer registry follow-up of phase III trial cohorts and an age-aligned cohort of unvaccinated women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>These individually and\/or clusterrandomized cohorts of HPV6\/11\/16\/18- and HPV16\/18-vaccinated and unvaccinated women were enrolled, respectively, in 2002, 2004, and 2003\/2005. The trial cohorts comprised initially 16- to 17-year-old HPV6\/11\/16\/18-vaccinated FUTURE II (NCT00092534) participants (866) and HPV16\/18-vaccinated PATRICIA (NCT00122681) and 012 trial (NCT00169494) participants (2,465), and 16,526 initially 16- to 19-year-old unvaccinated controls. After active 4-year clinical follow-up, passive, country-wide Finnish Cancer Registry (FCR) follow-up for cervical intraepithelial neoplasia grade 3 (CIN3) and adenocarcinoma in situ (AIS) was based on consented use of unique personal identifiers and started 6 months after the end of the FUTURE II and PATRICIA trials in 2007 and 2009, and ended at the end of 2019. The follow-up with altogether 229,020 follow-up years was age-aligned to ensure that similarly aged cohorts were passively followed up for 15 years post=vaccination for the intention-to-treat analyses of vaccine efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, we identified 5 and 16 CIN3 (no AIS) cases in the HPV6\/11\/16\/18 and HPV16\/18 cohorts, respectively, during the FCR-based follow-up. In the unvaccinated cohort, we identified 281 CIN3 cases, 20 AIS cases, and 13 cases with invasive cervical cancer. Vaccine efficacies against CIN3+ were 68.4% and 64.5% for the quadrivalent and the bivalent vaccines, respectively, with overlapping confidence intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Long-term follow-up of randomized, initially adolescent HPV-vaccinated and unvaccinated cohorts shows, in this head-to-head setting, that the bivalent and quadrivalent HPV vaccines are equally effective against immediate precursors of cervical cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2024.1437704","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T01:10:46Z","timestamp":1725844246000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ\u2014population-based follow-up of two cluster-randomized trials"],"prefix":"10.3389","volume":"14","author":[{"given":"Matti","family":"Lehtinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapio","family":"Luostarinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiina","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Apter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Harjula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaisa","family":"Heikkil\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Hokkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjo","family":"Kuortti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Nieminen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervi","family":"Nummela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorma","family":"Paavonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Palmroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiina","family":"Pet\u00e4j\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville N.","family":"Pimenoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eero","family":"Pukkala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Dillner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"f5906","DOI":"10.1136\/bmj.f5906","article-title":"Autoimmune, neuro- logical, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden","volume":"347","author":"Arnheim","year":"2013","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/infdis\/jiac190","article-title":"Head-to-head comparison of type-specific peak pseudovirion antibody levels induced by three doses of the bivalent vs. nonavalent human papillomavirus vaccines","volume":"226","author":"Arroyo","year":"2022","journal-title":"J. Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/infdis\/jiy545","article-title":"Long-term seroresponse to human papillomavirus vaccines. Up to 12 years follow-up in the Finnish Maternity Cohort","volume":"219","author":"Artemchuk","year":"2019","journal-title":"J. Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3109\/13625187.2013.801953","article-title":"Impact of HPV16\/18 vaccination on quality of life","volume":"18","author":"Eriksson","year":"2013","journal-title":"Eur. J. Contracept. Reproduct. Health Care"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Comparing methods for calculating confidence intervals for vaccine efficacy","volume":"15","author":"Ewell","year":"1996","journal-title":"Stat. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/infdis\/jiaa617","article-title":"Sustained cross-reactive antibody responses after human papillomavirus vaccinations. Up to 12 years follow-up in the Finnish Maternity Cohort","volume":"223","author":"Kann","year":"2021","journal-title":"J. Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eclinm.2020.100401","article-title":"Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries","volume":"23","author":"Kjaer","year":"2020","journal-title":"EClinicalMedicine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1258\/095646206778145550","article-title":"Enrolment of 22,000 adolescents to a population based HPV vaccination trial","volume":"17","author":"Lehtinen","year":"2006","journal-title":"Int. J. STD AIDS"},{"key":"B9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrclinonc.2013.84","article-title":"Clinical trials of human papillomavirus vaccines and beyond","volume":"10","author":"Lehtinen","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1080\/21645515.2016.1183847","article-title":"Safety of human papillomavirus (HPV) 16\/18 vaccine in early adolescents: Interim analysis of a large community-randomized controlled trial","volume":"12","author":"Lehtinen","year":"2016","journal-title":"Hum. Vac. Immunother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.vaccine.2006.05.109","article-title":"Studies to assess long-term efficacy and effectiveness of HPV vaccination in developed and developing countries","volume":"24","author":"Lehtinen","year":"2006","journal-title":"Vaccine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1258\/095646206776253453","article-title":"Population based enrolment of adolescent girls into long-term human papillomavirus vaccination trial","volume":"17","author":"Lehtinen","year":"2006","journal-title":"Int. J. STD AIDS"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-050669","article-title":"Human papillomavirus vaccine efficacy against invasive HPV-positive cancers: population-based follow-up of a cluster-randomized trial","volume":"11","author":"Lehtinen","year":"2021","journal-title":"BMJ Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-015867","article-title":"Ten year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point \u2013 registry-based follow-up of randomized trial cohorts","volume":"7","author":"Lehtinen","year":"2017","journal-title":"BMJ Open"},{"key":"B15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 vaccine against the most stringent cervical pre-cancer end-points: end-of study report of a double blind, randomized trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1002\/cam4.1222","article-title":"Cancer registry follow-up for 17M person-yrs of a nationwide maternity cohort","volume":"6","author":"Lehtinen","year":"2017","journal-title":"Cancer Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/S1473-3099(20)30873-2","article-title":"Sustainability of bi- and quadrivalent HPV vaccine-induced neutralizing antibodies","volume":"10","author":"Mariz","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Mu\u00f1oz","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"B19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/02841860701203545","article-title":"Nordic biological specimen banks as basis for studies of cancer causes and control \u2013 25 million person-years and 100,000 prospective cancers","volume":"46","author":"Pukkala","year":"2007","journal-title":"Acta Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1002\/ijc.27971","article-title":"Cancer registry based follow-up in the understanding of long-term protection of HPV vaccinations against cervical carcinoma","volume":"132","author":"Rana","year":"2013","journal-title":"Int. J. Cancer"},{"key":"B21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/13625187.2010.536921","article-title":"Impact of HPV vaccination on quality of life","volume":"16","author":"Woodhall","year":"2011","journal-title":"Eur. J. Contracept. Reproduct. Health Care"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1437704\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T01:10:50Z","timestamp":1725844250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1437704\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":21,"alternative-id":["10.3389\/fcimb.2024.1437704"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2024.1437704","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"article-number":"1437704"}}